| Ferrari, Alessandra |
PRIOH-1, NCT03073967 / 2020-004940-27: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects |
|
|
| Recruiting | 3 | 153 | Europe, Canada, US, RoW | Pritelivir, Investigator's choice, Foscarnet or Cidofovir or Imiquimod | AiCuris Anti-infective Cures AG, Medpace, Inc. | HSV Infection | 07/25 | 11/25 | | |
DEDALUS, NCT05128630: Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC. |
|
|
| Recruiting | 2 | 45 | Europe | Durvalumab, radotherapy, chemotherapy | IRCCS Policlinico S. Matteo | NSCLC, Stage III | 11/24 | 11/25 | | |
NCT06343272: Lymphocyte Enhancement in Gastroenteric Oncology |
|
|
| Recruiting | N/A | 54 | Europe | EAA supplementation, Isocaloric placebo | Fondazione IRCCS Policlinico San Matteo di Pavia, University of Pavia | Advanced Gastrointestinal Cancers | 12/24 | 02/25 | | |
| Recruiting | N/A | 100 | Europe | | Fondazione IRCCS Policlinico San Matteo di Pavia | Multiple Myeloma | 02/28 | 08/28 | | |
NCT04364776: Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC. |
|
|
| Active, not recruiting | N/A | 100 | Europe | Durvalumab | IRCCS Policlinico S. Matteo | Lung Cancer, Lung Cancer Stage III | 12/23 | 12/24 | | |
NCT06347588: Risk of Reactivation of Occult Hepatitis B in Cancer Patients During Immunotherapy. |
|
|
| Not yet recruiting | N/A | 60 | Europe | Observational: Blood sample of HVB-specific Elispot assay, HBSAg, HBV-DNA | Fondazione IRCCS Policlinico San Matteo di Pavia | Occult Hepatitis B Infection in Cancer Patients | 05/26 | 12/26 | | |
MelMarT-II, NCT03860883: Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma |
|
|
| Recruiting | N/A | 2998 | Europe, Canada, US, RoW | Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin | Melanoma and Skin Cancer Trials Limited, Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre | Cutaneous Melanoma, Stage II | 12/29 | 12/34 | | |
| Lamorte, Giuseppe |
PRIOH-1, NCT03073967 / 2020-004940-27: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects |
|
|
| Recruiting | 3 | 153 | Europe, Canada, US, RoW | Pritelivir, Investigator's choice, Foscarnet or Cidofovir or Imiquimod | AiCuris Anti-infective Cures AG, Medpace, Inc. | HSV Infection | 07/25 | 11/25 | | |
